Ionis Pharmaceuticals on Monday said it had earned a $45m fee from Roche after the Swiss peer took up its option to licence its Huntington's disease treatment. A key trial of the Ionis-HTT drug, which took place in the UK Germany and Canada, produced positive results, successfully lowering the level of the harmful Huntington protein in the nervous system. The trial of 46 patients was led by Professor Sarah Tabrizi of the UCL Institute of Neurology and sponsored by Ionis. Each patient received ...Den vollständigen Artikel lesen ...